Myeloid Malignancy Workshop

Friday, March 8, 2024, 7:00 AM - 6:00 PM, Leon & Norma Hess Center for Science and Medicine, Davis Auditorium, 1470 Madison Avenue, New York, NY


The Myeloid Malignancy Workshop will be a one day in-person event focused on the science and medicine of myelodysplastic syndromes, myeloproliferative neoplasms, and acute myeloid leukemia. The workshop will include internationally recognized clinical and laboratory experts in the field that will provide focused talks intended to highlight the cutting edge science and recent evidence-based advances in clinical care of myeloid malignancies.

1. Understand the molecular and immunologic vulnerabilities driving drug development for MDS, MPN and AML
2. Select the appropriate evidence based therapies for patients with myeloid malignancies
3. Recognize the remaining unmet needs in treating myeloid malignancies
4. Discuss strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
5. Discuss the emerging results of clinical trials that are investigating therapies in AML/MDS
6. Identify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors

Registration Fees	In-Person	Virtual
Physicians	$100	$75
Lab Based	$50	$25
Industry	$150	$125
Residents/Fellows/Trainee	$0	$0
Nurses, NP's, PA's, Pharmacy	$0	$0

* Complimentary attendance with a letter from you program director or copy of hospital ID. Proof must be emailed to [email protected].

Cancellation Policy
All refund and cancellation requests must be emailed to the CME office at [email protected] by February 8, 2024. Cancellations after this date are not eligible for a refund. An administrative fee of $50 will be deducted from your refund. No refunds will be issued for registration fees that are equal to or less than $50.00. No refunds will be issued for “no-shows.”

Meeting Location
Davis Auditorium
1470 Madison Avenue, 2nd Floor
New York, NY 10029

The Myeloid Malignancy Workshop committee encourages you to submit applications for both the Dr. Ronald Hoffman Translational Research Award and the Dr. Ruben Mesa Young Clinical Investigator Award. Your submissions will undergo assessment by a panel of five esteemed experts in their respective domains. To ensure impartial evaluation, reviewers will conduct assessments without access to applicants' identifying information.

Award Details:
One recipient will be chosen for each award by the review committee, with each winner receiving a $25,000 grant to further their research. Additionally, we will extend invitations to each winner to deliver a 5-minute presentation showcasing their research at the Myeloid Malignancy Workshop at Mount Sinai on March 8th, 2024.

For more details regarding eligibility and application deadlines please follow the application link: https://redcap.mountsinai.org/redcap/surveys/?s=JX8RWHFXCFEADKJ9

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (5.50 hours), Non-Physician Attendance (5.50 hours)

If you would like assistance with hotel arrangements, please contact our Housing Manager, Denise Newman by email: [email protected] or call 718-835-4911

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

It is the policy of Icahn School of Medicine at Mount Sinai (ISMMS) to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-accredited educational activities. All faculty participating in the planning or implementation of an activity accredited by ISMMS are expected to disclose all of their financial relationships with ineligible companies existing within the prior 24 months. Relevant financial relationships will be mitigated and disclosed to learners before the activity takes place. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material..
Myeloid Maligncy Workshop

Friday, March 8, 2024